1. Home
  2. ACRS vs VOGX Comparison

ACRS vs VOGX Comparison

Compare ACRS & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Logo Vogenx Inc Common Stock

VOGX

Vogenx Inc Common Stock

N/A

Current Price

$11.94

Market Cap

482.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
VOGX
Founded
2012
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
482.8M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
ACRS
VOGX
Price
$3.45
$11.94
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $9.82
N/A
AVG Volume (30 Days)
★ 2.6M
81.7K
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
★ N/A
N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$11.51
52 Week High
$6.60
$38.41

Technical Indicators

Market Signals
Indicator
ACRS
VOGX
Relative Strength Index (RSI) 39.18 31.95
Support Level $3.24 N/A
Resistance Level $4.60 $22.10
Average True Range (ATR) 0.28 2.33
MACD -0.02 -0.64
Stochastic Oscillator 17.03 5.31

Price Performance

Historical Comparison
ACRS
VOGX

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About VOGX Vogenx Inc Common Stock

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Share on Social Networks: